PDF(Pubmed)
Abstract：
UNASSIGNED: Sarcopenia is a common complication of liver cirrhosis and can be used for predicting dismal prognostic outcomes. This study aimed to evaluate the role of sarcopenia in rebleeding and mortality of liver cirrhosis patients after endoscopic therapy.
UNASSIGNED: The liver cirrhosis patients who received endoscopic treatment were enrolled. Propensity score matching (PSM) was used to overcome selection bias. Two-year rebleeding episodes and mortality after endoscopic therapy were recorded.
UNASSIGNED: A total of 109 (32.4%) sarcopenia patients were reported. Before PSM, the frequency of rebleeding was significantly higher in the sarcopenia group relative to the non-sarcopenia group (41.3% vs. 15.9%, p < 0.001). Moreover, the multivariable analysis revealed that sarcopenia (p < 0.001, HR:2.596, 95% CI 1.591-4.237) was independently associated with a 2-year rebleeding episode. After PSM, the sarcopenia group exhibited an increased rebleeding rate as compared with non-sarcopenia group (44.4% vs. 15.3%, p < 0.001). According to multivariable analysis, sarcopenia (p < 0.001, HR:3.490, 95% CI 1.756-6.938) was identified as a significant predictor for 2-year rebleeding.
UNASSIGNED: Sarcopenia was significantly associated with a high 2-year rebleeding rate in liver cirrhosis patients after endoscopic treatment. Therefore, the precise evaluation of a patient\'s nutritional status, including sarcopenia becomes mandatory before endoscopic treatment.
UNASSIGNED: The liver cirrhosis patients who received endoscopic treatment were enrolled. Propensity score matching (PSM) was used to overcome selection bias. Two-year rebleeding episodes and mortality after endoscopic therapy were recorded.
UNASSIGNED: A total of 109 (32.4%) sarcopenia patients were reported. Before PSM, the frequency of rebleeding was significantly higher in the sarcopenia group relative to the non-sarcopenia group (41.3% vs. 15.9%, p < 0.001). Moreover, the multivariable analysis revealed that sarcopenia (p < 0.001, HR:2.596, 95% CI 1.591-4.237) was independently associated with a 2-year rebleeding episode. After PSM, the sarcopenia group exhibited an increased rebleeding rate as compared with non-sarcopenia group (44.4% vs. 15.3%, p < 0.001). According to multivariable analysis, sarcopenia (p < 0.001, HR:3.490, 95% CI 1.756-6.938) was identified as a significant predictor for 2-year rebleeding.
UNASSIGNED: Sarcopenia was significantly associated with a high 2-year rebleeding rate in liver cirrhosis patients after endoscopic treatment. Therefore, the precise evaluation of a patient\'s nutritional status, including sarcopenia becomes mandatory before endoscopic treatment.
摘要：
■肌肉减少症是肝硬化的常见并发症，可用于预测预后不良。本研究旨在评估肌少症在肝硬化患者内镜治疗后再出血和死亡中的作用。
■纳入接受内镜治疗的肝硬化患者。倾向评分匹配(PSM)用于克服选择偏倚。记录内镜治疗后两年再出血事件和死亡率。
■共报告109例（32.4%）肌肉减少症患者。在PSM之前,肌肉减少组的再出血频率明显高于非肌肉减少组(41.3%vs.15.9%,p<0.001)。此外，多变量分析显示,肌少症(p<0.001,HR:2.596,95%CI1.591-4.237)与2年再出血事件独立相关.PSM之后,与非肌肉减少组相比，肌肉减少组再出血率增加(44.4%vs.15.3%,p<0.001)。根据多变量分析，肌肉减少症(p<0.001,HR:3.490,95%CI1.756-6.938)是2年再出血的重要预测因子。
■肝硬化患者内镜治疗后2年高再出血率显著相关。因此,对患者营养状况的精确评估，包括肌少症在内镜治疗前成为强制性的。
■纳入接受内镜治疗的肝硬化患者。倾向评分匹配(PSM)用于克服选择偏倚。记录内镜治疗后两年再出血事件和死亡率。
■共报告109例（32.4%）肌肉减少症患者。在PSM之前,肌肉减少组的再出血频率明显高于非肌肉减少组(41.3%vs.15.9%,p<0.001)。此外，多变量分析显示,肌少症(p<0.001,HR:2.596,95%CI1.591-4.237)与2年再出血事件独立相关.PSM之后,与非肌肉减少组相比，肌肉减少组再出血率增加(44.4%vs.15.3%,p<0.001)。根据多变量分析，肌肉减少症(p<0.001,HR:3.490,95%CI1.756-6.938)是2年再出血的重要预测因子。
■肝硬化患者内镜治疗后2年高再出血率显著相关。因此,对患者营养状况的精确评估，包括肌少症在内镜治疗前成为强制性的。
